NDA 019839 · Viatris
Zoloft
Sertraline Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Dec 30, 1991
Approved uses
13
Original approval plus efficacy supplements
Registered trials
369
75 Phase 3, 32 recruiting
FAERS reports
106,461
67,510 serious, 7,543 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [See Warnings and Precautions (5.1) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients ( 5.1 ) • Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 )
What it is approved for
From the label in effect Aug 8, 2023.
ZOLOFT is indicated for the treatment of the following [See Clinical Studies (14) ] : • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder (SAD) • Premenstrual dysphoric disorder (PMDD) ZOLOFT is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder (SAD) • Premenstrual dysphoric disorder (PMDD)
Mechanism: Sertraline potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 19, 2004 Supplement 47 · Efficacy LetterLabel
- Sep 16, 2003 Supplement 44 · Efficacy Pediatric Medical ReviewPediatric Statistical ReviewPediatric Written Request
- Feb 7, 2003 Supplement 45 · Efficacy LabelLetter
- Sep 20, 2002 Supplement 36 · Efficacy Letter
- Sep 20, 2002 Supplement 34 · Efficacy
- May 16, 2002 Supplement 39 · Efficacy LetterLabel
- Oct 12, 2001 Supplement 33 · Efficacy LetterLabel
- Aug 6, 2001 Supplement 35 · Efficacy LetterReviewLabel
- Dec 7, 1999 Supplement 26 · Efficacy LabelLetterReview
- Oct 10, 1997 Supplement 17 · Efficacy Review
- Jul 8, 1997 Supplement 11 · Efficacy Review
- Oct 25, 1996 Supplement 2 · Efficacy
- Dec 30, 1991 Original approval · Type 1 - New Molecular Entity Other Important Information from FDA
5 products under this application
- ZOLOFT · SERTRALINE HYDROCHLORIDE EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- ZOLOFT · SERTRALINE HYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
- ZOLOFT · SERTRALINE HYDROCHLORIDE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB
- ZOLOFT · SERTRALINE HYDROCHLORIDE EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- ZOLOFT · SERTRALINE HYDROCHLORIDE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sertraline" as an intervention, any sponsor and status, largest first.
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in PakistanPivotal-lookingRecruiting
Pakistan Institute of Living and LearningAcademic, hospital or other
NCT07015944 · 26,376 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 30, 2028
Drug: Standardised pharmacological treatment (antidepressants) · For: Major Depressive Disorder (MDD); Breast Cancer Survivor
Sites: Karachi, Pakistan
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- International Study to Predict Optimised Treatment - in DepressionPivotal-lookingStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00693849 · 2,688 participants (planned) · Start Sep 2008 · Primary completion Dec 2019
Drug: Escitalopram; Sertraline and 1 more · For: Major Depressive Disorder
Sites: Colton, California; Mission Viejo, California; Stanford, California · 20 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Strategic Use of New Generation Antidepressants for DepressionPivotal-lookingCompleted
Kyoto UniversityAcademic, hospital or other
NCT01109693 · 2,011 participants · Start Dec 2010 · Primary completion Sep 2015
Drug: Sertraline; Mirtazapine · For: Unipolar Major Depressive Episode
Sites: Nagoya, Japan; Nangoku, Japan
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea7,583
- fatigue7,146
- drug ineffective6,961
- headache6,380
- anxiety5,948
- depression5,895
- pain5,248
- diarrhoea5,226
- dizziness5,121
- dyspnoea4,629
- insomnia4,136
- vomiting4,129
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,246 |
| 2005 | 3,227 |
| 2006 | 2,879 |
| 2007 | 2,463 |
| 2008 | 2,089 |
| 2009 | 2,791 |
| 2010 | 5,405 |
| 2011 | 6,158 |
| 2012 | 7,062 |
| 2013 | 4,978 |
| 2014 | 4,537 |
| 2015 | 6,116 |
| 2016 | 6,178 |
| 2017 | 5,666 |
| 2018 | 5,359 |
| 2019 | 5,166 |
| 2020 | 4,843 |
| 2021 | 4,310 |
| 2022 | 5,429 |
| 2023 | 4,539 |
| 2024 | 4,772 |
| 2025 | 5,160 |
| 2026 | 4,083 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zoloft (Sertraline HCl)
2024 spending
$14.1M
Beneficiaries
2,841
13,450 claims
Per beneficiary
$4,977
$13.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,100,083 |
| 2021 | $15,325,746 |
| 2022 | $14,396,286 |
| 2023 | $13,954,039 |
| 2024 | $14,138,763 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial.
Davis LL, Behl S, Lee D, et al. · JAMA Psychiatry 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.
Walkup JT, Albano AM, Piacentini J, et al. · N Engl J Med 2008 · Multicenter Study, Randomized Controlled Trial
- Selection of the optimal dose of sertraline for depression: A dose-response meta-analysis of randomized controlled trials.
Luo X, Zhu D, Li J, et al. · Psychiatry Res 2023 · Meta-Analysis, Review
- Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches.
Hoskins MD, Bridges J, Sinnerton R, et al. · Eur J Psychotraumatol 2021 · Meta-Analysis, Systematic Review
- Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review.
Wu T, Song F, Cao W, et al. · BMC Psychiatry 2025 · Systematic Review, Comparative Study
Sponsor: Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.